Despite the potential benefits, targeting STAT proteins presents several challenges. One major hurdle is the difficulty in specifically inhibiting STAT activity without affecting normal cellular functions, given their role in essential physiological processes. Additionally, cancer cells may develop resistance to STAT inhibitors through various mechanisms, necessitating the need for combination therapies and further research to overcome these obstacles.
